pharma
Novartis
NovaPharmaNews editorial coverage mentioning Novartis — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Basel, CH
- Programs
- 0
- Drugs
- 0
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Novartis — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Novartis — regulatory, clinical, and market analysis.
Novartis remibrutinib wins Phase 3 in CSU: what it means
Novartis remibrutinib is an oral, highly selective BTK inhibitor with Phase 3 success in chronic spontaneous urticaria. This plan frames the catalyst for BD teams, investors, and analysts, including efficacy, safety, and next milestones.
Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria
Novartis remibrutinib has Phase 3 support in chronic spontaneous urticaria, with evidence of early symptom improvement and sustained efficacy through 52 weeks. This plan frames the result for BD teams, investors, and analysts, including regulatory context and what to watch next.
Novartis and AbbVie Layoffs: Implications for the Pharma Industry
Novartis and AbbVie are planning significant layoffs this summer. This article examines the implications for the pharmaceutical industry and business teams.
BMS Expands in Texas While Novartis Faces Tenant Challenges
Bristol Myers Squibb is planning a new campus in Texas, while Novartis is facing eviction issues with a tenant in Slovenia. These developments could reshape the competitive landscape.